US Broker Ratings

AdaptHealth Corp. (AHCO) Stock Analysis: A 32% Upside Awaits Investors in the Home Medical Equipment Sector

AdaptHealth Corp. (NASDAQ: AHCO) is strategically positioned in the healthcare sector, specifically within the medical devices industry. Specializing in the distribution of home medical equipment (HME) and services, AdaptHealth serves..

Artivion, Inc. (AORT) Investor Outlook: Potential Upside of 25.43% and Strong Buy Ratings

Artivion, Inc. (NYSE: AORT), a prominent player in the healthcare sector, specifically within the medical devices industry, is capturing investor attention with a noteworthy potential upside of 25.43%. This Georgia-based..

Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and a 57% Potential Upside

Harrow, Inc. (NASDAQ: HROW), a growing player in the healthcare sector, is making waves in the pharmaceutical industry, particularly in the realm of ophthalmic solutions. With a market capitalization of..

Amphastar Pharmaceuticals (AMPH): Investor Outlook with 13% Potential Upside

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) stands as an intriguing prospect within the healthcare sector, particularly in the niche of specialty and generic drug manufacturing. With a market capitalization of $1.3..

Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unlocking a 40% Potential Upside in Non-Opioid Pain Management Solutions

Investors eyeing opportunities in the healthcare sector may find Pacira BioSciences, Inc. (NASDAQ: PCRX) a compelling option, given its focus on non-opioid pain management and regenerative health solutions. With a..

agilon health, inc. (AGL) Stock Analysis: Navigating a 19% Potential Upside Amidst Challenges

For investors with a keen eye on the healthcare sector, agilon health, inc. (NYSE: AGL) presents a complex but intriguing opportunity. Despite some concerning metrics in its financials, the company..

Innoviva, Inc. (INVA) Stock Analysis: Unveiling a Potential 54.91% Upside in the Biotechnology Sector

Innoviva, Inc. (NASDAQ: INVA), a prominent player in the healthcare sector, particularly within the biotechnology industry, is capturing investor attention with its robust growth prospects and strategic partnerships. Headquartered in..

Structure Therapeutics Inc. (GPCR): Analyst Ratings Suggest Nearly 20% Upside Potential

Structure Therapeutics Inc. (NASDAQ: GPCR), a key player in the biotechnology sector, has captured investor attention with its innovative approach to addressing chronic diseases. With a market capitalization of $6.35..

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring a Potential 116% Upside in Biotech Innovation

Celldex Therapeutics, Inc. (NASDAQ: CLDX), a prominent player in the biotechnology sector, is making waves within the healthcare industry. The company, based in Hampton, New Jersey, is dedicated to the..

Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges

Novavax, Inc. (NASDAQ: NVAX), a prominent player in the biotechnology sector, is recognized for its innovative approach to vaccine development. With a market capitalization of $1.41 billion, Novavax operates from..

Wave Life Sciences Ltd. (WVE): Analyst Consensus Highlights 143.73% Potential Upside for Biotech Innovator

Wave Life Sciences Ltd. (NASDAQ: WVE) is making waves in the biotechnology sector with its innovative approach to RNA medicine development. The Singapore-based clinical-stage company is gaining investor attention, particularly..

Edgewise Therapeutics (EWTX): Analyst Consensus Reveals a 32% Upside Potential

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a dynamic presence in the biotechnology sector, is drawing significant attention in the investment community. Specializing in the development of therapies for muscle disorders, this..

Integra LifeSciences Holdings C (IART) Stock Analysis: A 38.89% Potential Upside in the Medical Devices Sector

Integra LifeSciences Holdings Corporation (NASDAQ: IART) stands as a notable player in the healthcare sector, specifically within the medical devices industry. Headquartered in Princeton, New Jersey, Integra LifeSciences has carved..

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 226.80% Upside

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), a prominent player in the specialty and generic drug manufacturing industry, presents an intriguing investment opportunity with its potential upside of 226.80%. This North Carolina-based..

10x Genomics, Inc. (TXG) Stock Analysis: Navigating Market Volatility and Growth Challenges

10x Genomics, Inc. (NASDAQ: TXG) is a prominent player in the healthcare sector, specifically within the health information services industry. The company, headquartered in Pleasanton, California, has carved a niche..

MannKind Corporation (MNKD) Stock Analysis: A Promising 59.92% Upside with Strong Buy Ratings

MannKind Corporation (NASDAQ: MNKD) stands out in the biotechnology sector with its innovative focus on therapeutic products for endocrine and orphan lung diseases. Based in Danbury, Connecticut, MannKind has carved..

Schrodinger, Inc. (SDGR) Investor Outlook: Unveiling a 77.43% Potential Upside Amidst Innovative Drug Discovery and Software Growth

Schrodinger, Inc. (NASDAQ: SDGR), a pivotal player in the healthcare sector’s Health Information Services industry, is capturing investor attention with a striking 77.43% potential upside. This New York-based company, founded..

PACS Group, Inc. (PACS)

⚠️ No article content returned.

..

Kestra Medical Technologies (KMTS) Stock Analysis: Exploring a 16% Potential Upside

Kestra Medical Technologies, Ltd. (KMTS) stands at the intersection of healthcare innovation and investment opportunity. This Kirkland, Washington-based company, with a market capitalization of $1.46 billion, is making notable strides..

ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Promising 37.97% Upside Awaits Investors

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a notable player in the healthcare industry, specifically within the drug manufacturing sector, presents an intriguing opportunity for investors seeking growth in the biopharmaceutical space...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds